

**BRONSTER FUJICHAKU ROBBINS**

A Law Corporation

MARGERY S. BRONSTER 4750  
ROBERT M. HATCH 7724  
1003 Bishop Street, Suite 2300  
Honolulu, Hawai‘i 96813  
Telephone: (808) 524-5644  
Facsimile: (808) 599-1881  
E-mail: [mbronster@bfrhawaii.com](mailto:mbronster@bfrhawaii.com)  
[rhatch@bfrhawaii.com](mailto:rhatch@bfrhawaii.com)

**WISNER BAUM, L.L.P**

R. BRENT WISNER, ESQ. (SBN: 276023) (*Pro Hac Vice Forthcoming*)  
STEPHANIE B. SHERMAN, ESQ. (SBN: 338390) (*Pro Hac Vice Forthcoming*)  
11111 Santa Monica Boulevard, Suite 1750  
Los Angeles, CA 90025  
Telephone: (310) 207-3233  
Facsimile: (310) 820-7444  
E-mail: [bwisner@wisnerbaum.com](mailto:bwisner@wisnerbaum.com)  
[ssherman@wisnerbaum.com](mailto:ssherman@wisnerbaum.com)

*Attorneys for Plaintiff and the Proposed Classes*

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF HAWAI‘I

JENNIFER SNOW on behalf of herself,  
and all others similarly situated, and the  
general public,

Plaintiff,

v.

L’OREAL USA, Inc. and DOES 1 to 50,  
Inclusive.

Defendant.

Civil No.

**CLASS ACTION COMPLAINT;  
DEMAND FOR JURY TRIAL;  
SUMMONS**

**TABLE OF CONTENTS**

	Page(s)
I. INTRODUCTION.....	1
II. THE PARTIES .....	7
III. JURISDICTION AND VENUE.....	8
IV. GENERAL ALLEGATIONS.....	9
A. DEFENDANT DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE BPO PRODUCTS TO THE PUBLIC.....	10
B. DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND STORAGE.....	12
C. DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST THE BPO PRODUCTS.....	16
D. DEFENDANT IGNORED FDA’S BENZENE ALERT TO TEST THEIR BPO PRODUCTS .....	17
E. RECENT TESTING FOUND COMMON BPO PRODUCTS CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS .....	18
F. DEFENDANT EXPOSED PLAINTIFF, THE CLASS, AND THE PUBLIC TO BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE.....	24
G. DEFENDANT PUBLICLY AFFIRMED IT WAS FOUNDED ON “SCIENCE AND SAFETY” BUT CONCEALED ITS FAILURE TO TEST THE BPO PRODUCTS FOR SAFETY .....	28
H. DEFENDANT DID NOT WARN PLAINTIFF, THE CLASS, AND SUBCLASSES THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION.....	30

I.	DEFENDANT DIRECTLY MARKETED BPO PRODUCTS TO CHILDREN AND TEENAGERS WHEN THEY KNEW OR SHOULD HAVE KNOW OF THE RISK OF BENZENE CONTAMINATION ...	30
V.	PUNITIVE DAMAGES ALLEGATIONS .....	32
VI.	PLAINTIFF SPECIFIC ALLEGATIONS .....	34
VII.	CLASS ACTION ALLEGATIONS.....	35
VIII.	CAUSES OF ACTION .....	40
A.	VIOLETION OF CALIFORNIA’S UNFAIR COMPETITION LAW BUS. & PROF. CODE § 17200 <i>et seq.</i> , <i>on Behalf of the California Subclass</i> .....	40
B.	VIOLETION OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, CAL. CIV. CODE § 1750, <i>et seq.</i> , <i>on Behalf of the California Subclass</i> .....	44
C.	FALSE ADVERTISING UNDER VARIOUS STATE STATUTES, <i>on Behalf of the California, Hawaii, and New York Subclasses</i> .....	47
D.	DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES, <i>on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i> .....	51
E.	BREACH OF EXPRESS WARRANTY, <i>on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i> .....	57
F.	BREACH OF IMPLIED WARRANTY, <i>on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i> .....	59
G.	UNJUST ENRICHMENT, <i>on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses</i> .....	61
IX.	PRAYER FOR RELIEF .....	62

## **CLASS ACTION COMPLAINT**

Plaintiff, JENNIFER SNOW, on behalf of herself, the proposed Class and Subclasses defined below, and the public, brings this Class Action Complaint (“Class Action”) against Defendant, alleging the following upon Plaintiff’s personal knowledge, or where Plaintiff lacks personal knowledge, upon information and belief, including the investigation of counsel.

### **I. INTRODUCTION**

1. This is a consumer fraud Class Action to redress the economic harms caused by Defendant’s sale of benzoyl peroxide acne treatment drug products (“BPO Products” or “Products”) without warning consumers the BPO Products contain unsafe levels of the potent human carcinogen benzene, and that the BPO Products were at risk of degrading further into benzene under normal use, handling, and storage conditions.

2. The BPO Products are “drugs” used to treat acne vulgaris (“acne”), formulated with a chemical called benzoyl peroxide (“BPO”), along with other inactive ingredients, to make acne treatment creams, washes, scrubs, and bars. Before being sold to the public, the Products must be made in conformity with current good manufacturing practices and must conform to quality, safety, and purity specifications. Defendant’s BPO Products did not.

3. BPO Products should not contain benzene, nor degrade into benzene, except under extraordinary circumstances.<sup>1</sup> A drug is adulterated if it consists in whole or in part of any filthy, putrid, or decomposed substance, is impure, or mixed with another substance.<sup>2</sup> Under the FDA Act it is a crime to introduce or deliver “into interstate commerce any food, drug, device, tobacco product, or cosmetic that is adulterated or misbranded.”<sup>3</sup> If benzene is found in any on-market or post-market Product, the drug manufacture must contact the FDA to initiate a voluntary recall.<sup>4</sup>

4. Throughout this Complaint, references to federal law and FDA regulation are merely to provide context and are not intended to raise a federal question of law. All claims alleged herein arise out of violations of state law, which in no way conflict, interfere with, or impose obligations that are materially different than those imposed by federal law.

5. The BPO Products marketed and sold to Plaintiff, the Class, the Subclasses, and the public by the Defendant decomposed into benzene rendering them materially different than advertised, i.e., by containing unsafe levels of benzene. Benzene is a known human carcinogen. Studies dating to the 1800s have led to a consensus within the medical and scientific communities that benzene exposure, even

---

<sup>1</sup> Food and Drug Administration, *Q3C – Tables and List Guidance for Industry* (2017), <https://www.fda.gov/media/71737/download>.

<sup>2</sup> 21 U.S.C. § 351(a)(2011); *see also* § 351(b)-(d) (noting that a lack of purity or mixture with another substance also renders drug adulterated).

<sup>3</sup> 21 U.S.C. § 331(a)(2010).

<sup>4</sup> Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, <https://www.fda.gov/drugs/pharmaceutical-quality-resources/fda-alerts-drug->

in low amounts, increases the risk of blood cancers and other adverse effects.

6. In 2023, Valisure, LLC,<sup>5</sup> an independent, accredited laboratory that has developed analytical methods to test drugs and consumer products for public safety, tested a representative sample of BPO and non-BPO products and found the BPO Products had dangerous levels of benzene, many multiple times higher than allowed in any regulated drug.<sup>6</sup> Using industry standard gas chromatography and detection by mass spectrometry (“GC-MS”) instrumentation, with selected ion flow tube mass spectrometry (“SIFT-MS”) for detection of benzene released into the air around certain BPO Products, the Products were incubated to temperatures common during consumer use, handling, and storage and then sampled for benzene.<sup>7</sup> Levels as high as 1600 ppm were found in common BPO Products.<sup>8</sup> Unexpectedly, researchers found that benzene was released into the surrounding air even when the BPO Products’

---

manufacturers-risk-benzene-contamination-certain drugs (last visited Feb. 9, 2024).

<sup>5</sup> Valisure is an independent third-party analytical laboratory that is accredited to International Organization for Standardization (“ISO/IEC”) 17025:2017 standards for chemical testing (PJLA Accreditation Number 94238). In response to rising concerns about drug shortages, generics, and overseas manufacturing, Valisure developed and validated methods to test medications and consumer products distributed in the United States. Valisure has tested a variety of drug and consumer healthcare products for benzene including sunscreens, antiperspirants, body sprays, hand sanitizers, and dry shampoos for benzene. Valisure’s testing results submitted to the FDA in its Citizen’s Petitions, were widely publicized in the media leading to numerous recalls of contaminated consumer products. *See* Valisure Citizen’s Petition on Benzoyl Peroxide (March 4, 2024), pp. 6-7, *see also* Valisure Detects Benzene in Sunscreen, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>; Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; *see also* Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.

<sup>6</sup> Valisure FDA Citizen’s Petition on Benzoyl Peroxide (March 6, 2024).

<sup>7</sup> *Id.*

<sup>8</sup> *Id.* at p.17.

packaging was closed raising concern for even more inhalation exposures—a particularly pernicious form of exposure to benzene.<sup>9</sup> For the non-BPO products tested, benzene was not present, or at trace levels below 2 ppm.<sup>10</sup> Valisure filed a FDA Citizen’s Petition on March 5, 2024 demanding an immediate recall of all BPO Products.<sup>11</sup> The Petition is pending.<sup>12</sup>

7. The high levels of benzene found led Valisure to conduct a stability study on a diverse market sweep of BPO Products and formulations. Valisure’s results show that on-market BPO Products can form over 800 times the conditionally restricted FDA concentration limit of 2 parts per million (ppm) for benzene, and the evidence suggests this problem applies broadly to BPO products currently on the market.<sup>13</sup> Valisure concluded that on-market BPO Products appear to be fundamentally unstable and form unacceptably high levels of benzene when handled or stored at higher temperatures the Products may be exposed to during handling by consumers.<sup>14</sup>

8. Although the BPO Products have been found to have benzene, Defendant never listed benzene among the ingredients anywhere on the Products, labels, containers, in their advertising or on their websites. Defendant warned no one the

---

<sup>9</sup> *Id.* at p. 23.

<sup>10</sup> *Id.* at p. 15 (“76 non-BPO products had no detectable benzene or values below 0.1ppm. 6 non-BPO products contained traces of benzene below 2 ppm, which could be due to various inactive ingredients used in consumer products that have been theorized to contain trace benzene”); *see also* Valisure, LLC, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).

<sup>11</sup> Valisure’s FDA Benzoyl Peroxide Citizen’s Petition (March 5, 2024).

<sup>12</sup> Valisure’s FDA Petition was still pending as of this Class Action’s filing.


<sup>13</sup> Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).

<sup>14</sup> *Id.*

Products had benzene or were at risk of benzene contamination.

9. Defendant knew or should have known the BPO Products contain and/or degraded into benzene when exposed to expected consumer use, handling, and storage conditions. BPO is known, within the scientific community (but not among consumers) to degrade into benzene according to the mechanism below:<sup>15</sup>

10. Defendant misled Plaintiff, the Class, the Subclasses, and the public by



representing the BPO Products only had the ingredients listed, and not benzene.

Defendant misled Plaintiff, the Class, the Subclasses, and the public by representing the BPO Products were safe while concealing material health and safety information known to them, e.g., the BPO Products degraded to benzene, or were contaminated with benzene. Defendant misled Plaintiff, the Class, the Subclasses, and the public by

<sup>15</sup> The disposition of benzoyl peroxide to form benzene. Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The phenyl radicals can then produce benzene. See Shang-Hao Liu, et al, *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, Pages 68-76, , (2015), ISSN 0040-603, <https://www.sciencedirect.com/science/article/pii/S004060311500057X>.



giving the BPO Products long expiration dates of 2-3 years, affirming the BPO Products were safe for use for years when Defendant knew or should have known the BPO Products degraded much sooner to benzene under normal and expected consumer use, handling, and storage conditions.

11. Defendant's statements and omissions of material health and safety information unreasonably placed Plaintiff, the Class, the Subclasses, and the public at risk of exposure to benzene without their knowledge and consent. Defendant's statements were false, misleading, unsubstantiated, and blatantly deceptive.

12. As a result of the consumer deception, the Plaintiff, the Class, the Subclasses, and the public were economically harmed, as they purchased a product that they otherwise would have never purchased. They were also physically harmed by being exposed to a known human carcinogen.

13. This Class Action is necessary to redress the economic harms caused to Plaintiff, the Class, and the Subclass members who bought the Products believing them to be safe and only containing the ingredients on the BPO Products' labels, containers, in advertising, and on Defendant's websites. This Class Action is further necessary to expose Defendant's ongoing consumer fraud and to enjoin Defendant from continuing their misconduct and deception to protect the public.

14. Plaintiff brings this Class Action individually, and on behalf of those similarly situated, and seeks to represent a National Class of consumers who bought the Products, and State Subclasses of consumers from California, Connecticut,

Hawaii, Illinois, Maryland, Missouri, Massachusetts, Nevada, New York, Ohio, Pennsylvania, Rhode Island, and Washington (defined *infra*). Plaintiff seeks damages, reasonable attorneys' fees and costs, interest, restitution, other equitable relief, including an injunction and disgorgement of all benefits and profits Defendant received from their misconduct.

## II. THE PARTIES

15. Plaintiff Jennifer Snow is a Hawaii resident who bought BPO Products including L'Oreal's La Roche Effaclar Duo Dual Acne Treatment from May 2023 to October 2023. Plaintiff has suffered economic damages.

16. Defendant L'Oreal USA, Inc. ("L'Oreal") is a citizen of New York with its principal place of business at 10 Hudson Yards, New York, New York 10001. L'Oreal USA, Inc.'s BPO Product is Effaclar Duo Dual Acne Treatment. At all relevant times, L'Oreal conducted business and derived substantial revenue from its manufacturing, advertising, marketing, distributing, and selling of the Products within the State of Hawaii.

17. Defendant and its agents promoted, marketed, and sold the Products in Hawaii and in this District. The unfair, unlawful, deceptive, and misleading advertising and labeling of the Products were prepared and/or approved by Defendant and its agents and were disseminated by Defendant and its agents through labeling and advertising containing the misrepresentations alleged and disseminated uniformly through advertising, packaging, containers, and via websites and social media.

### III. JURISDICTION AND VENUE

18. This Court has jurisdiction over this matter because the amount in controversy exceeds \$5 million satisfying 28 U.S.C. § 1332(d)(2) for subject matter jurisdiction. This Court has supplemental jurisdiction over any state law claims under 28 U.S.C. § 1367.

19. Venue is proper in the District under 28 U.S.C. § 1391(b) because a substantial part of the events or omissions giving rise to the claims occurred in this District.

20. This Court has personal jurisdiction over the Defendant because Defendant transacts business in Hawaii, including in this District, has substantial aggregate contacts with the State of Hawaii, including in this District, engaged in misconduct that has and had a direct, substantial, reasonably foreseeable, and intended effect of injuring people in this District, and Defendant purposely availed itself of the benefits of doing business in the State of Hawaii, and in this District. Moreover, Plaintiff's claims arise out of and relate to the Defendant's actions and contacts with the State of Hawaii, and in this District.

21. To the extent applicable, the Court also has pendant personal jurisdiction over claims alleged against Defendant that involve the same common nucleus of facts and actions that give rise to Plaintiff's claims that otherwise have proper personal jurisdiction within this Court.

#### IV. GENERAL ALLEGATIONS

22. Fifty million Americans suffer from acne annually.<sup>16</sup> Acne is the most common skin condition in the United States with a prevalence among adolescents of almost 95 percent.<sup>17</sup> Acne can begin as early as age seven and, for some, can persist through adulthood and into ages 50s and 60s.<sup>18</sup> Millions of acne sufferers seek treatment every year making it a billion-dollar industry and a key business segment for Defendant, who is among America's most prominent companies.

23. Defendant's BPO Products are widely marketed, available, sold, and used by children, teenagers, and adults throughout the United States and the world. The acne treatment industry is a highly competitive billion-dollar market. To remain relevant and top of mind, Defendant spends millions of dollars every year promoting the Products directly to consumers, including teenagers. Defendant makes promises to consumers to influence their purchasing decisions such as affirming the Products are tested, backed by science, and approved by dermatologists. Defendants tell consumers they should buy their Products because Defendant is a market leader and well recognized around the world as beauty experts who only sell safe and tested Products.

24. Defendant's brand and name notoriety was well known to Plaintiff, the Class and Subclass members. L'Oreal is the largest cosmetics company in the world.

---

<sup>16</sup> American Association of Dermatology, <https://www.aad.org/media> (visited October 24, 2023).

<sup>17</sup> JL Burton et al., *The prevalence of acne vulgaris in adolescence*, BR J DERMATOL.,(1971);85(2):119–

L’Oreal is headquartered in Paris, France with its U.S. based companies located in New York City and El Segundo, California. L’Oreal USA is responsible for two-thirds of the cosmetic products sold in the U.S. making more than nine billion dollars annually in the U.S. and over 44 billion euros worldwide.<sup>19</sup> L’Oreal employs more than 600 researchers and scientists in the U.S. and 4,000 around the world.<sup>20</sup> L’Oreal markets itself as founded upon science and safety:

*L’Oréal was born from science, from a vision, created from the idea of a chemist. Since then, science has remained at the heart of our model. And it is without a doubt, the performance, safety and superior quality of our products that have been the foundation of our success for over 110 years. Our 4,000 researchers around the world have a single obsession: to innovate and offer our consumers, through our Brands, the best of science and create unequalled beauty experiences that meet the infinite diversity of their needs and aspirations.*

Barbara Lavernos, Deputy CEO, in charge of Research, Innovation and Technology.<sup>21</sup>

**A. DEFENDANT DID NOT COMPLY WITH FDA’S TESTING REQUIREMENTS BEFORE SELLING THE BPO PRODUCTS TO THE PUBLIC**

25. Despite Defendant’s worldwide name recognition, substantial market share of the beauty industry, and public affirmations that was “founded upon science

---

126.

<sup>18</sup> *Id.*

<sup>19</sup> L’Oreal Groupe, [www.loreal.com](http://www.loreal.com); see also, *L’Oreal Shares Plummet After Sales Miss*, <https://www.morningstar.com/news/dow-jones/202402094044/loreal-shares-plummet-after-sales-profit-miss> (last visited Feb. 11, 2024).

<sup>20</sup> L’Oreal Groupe, *Innovating Through Science*, <https://www.loreal.com/en/beauty-science-and-technology/beauty-research-and-innovation/innovating-through-science> (last visited Feb. 11, 2024).

<sup>21</sup> *Id.*

and safety,” Defendant did not adequately test their BPO Products before selling them to public. Defendant’s BPO Products are “drugs” regulated by the FDA. To make the finished BPO Products, BPO, a dry white powder, is mixed with other ingredients to create topical drug creams, cleansers, scrubs, and washes for use on the face and body. BPO is formulated into these BPO Products at concentrations up to 10%. As with any regulated drug, Defendant must follow current good manufacturing practices (“CGMPs”), have scientifically sound specifications, and must have test procedures and processes to ensure the drug’s components (active and inactive ingredients), and finished products are safe. Both raw ingredient materials and finished batches must be tested before released to the public to confirm they meet specifications for identity, strength, quality, and purity.<sup>22</sup> If testing results of the raw materials or finished product do not conform with the specifications, the product cannot be sold to the public. Defendant must also re-test any Products subject to deterioration.<sup>23</sup> Any Products not made in conformity with the CMGPs is considered “adulterated” under 501(a)(2)(B) of the Food, Drug, and Cosmetic Act.<sup>24</sup>

26. Defendant must also do stability testing to understand the “shelf life” of the Products and to assign an expiration date. It is well known that certain chemical

---

<sup>22</sup> 21 C.F.R. § 211.84 (1978); *see also* 21 C.F.R. § 211.160 (1978).

<sup>23</sup> 21 C.F.R. § 211.160(b)(1)(1978).

<sup>24</sup> 21 C.F.R. § 225.1 (1976). Under 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act a drug is considered “adulterated” (poorer in quality by adding another substance) if the methods used in, or the facilities or controls used for, its manufacture, processing, packing, or holding do not conform to or are not operated or administered in conformity with CGMP; *see also* Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

ingredients can degrade or change because of environmental, and storage conditions such as light, moisture, temperature, and humidity, or because of the passage of time. The stability testing should cover all expected distributor and consumer storage, handling, and use conditions and must be done using “reliable, meaningful, and specific test methods.”<sup>25</sup> If stability testing finds a drug product is not stable under expected storage or use conditions, degrades, or create toxic byproducts, the product cannot be sold to the public.

27. The CGMPs and stability test requirements are there to ensure drug products are safe for public use. These are the minimum requirements. Because the drug manufacturers are largely self-regulated, the FDA must rely on drug manufacturers, the public, and concerned citizens to report unsafe drugs. The FDA cannot force a drug manufacturer to recall a contaminated drug.<sup>26</sup>

**B. DEFENDANT KNEW OR SHOULD HAVE KNOWN THE BPO PRODUCTS DEGRADED TO BENZENE UNDER NORMAL USE, HANDLING, AND STORAGE**

28. Defendant knew or should have known the BPO Products degrade to benzene when exposed to heat. Defendant knew that, because of the chemical nature of the active and inactive ingredients, including BPO, the BPO Products were not stable and would degrade when exposed to heat from normal distributor and consumer


---

<sup>25</sup> 21 CFR 211.166.

<sup>26</sup> Food and Drug Administration, *Facts About the Current Good Manufacturing Practices (CGMP)*; <https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmp> (last visited Feb. 11, 2024).

use, handling, and storage conditions.

29. It is well known that BPO degrades to benzene when exposed to heat over time. This process was first reported in the scientific literature as early as 1936.<sup>27</sup> BPO degrades into benzene according to the mechanism below.<sup>28</sup>



30. The degradation of BPO to benzene was known or should have been known to the Defendant, who promoted itself as expending substantial sums of money and resources to science, research, and safety. Defendant marketed itself as a world class beauty company founded on science. Defendant employed high-level scientists, chemists, and researchers to formulate their Products for public use. Defendant of these resources and scientific expertise were aware of the well-known chemical processes that degrade their BPO Products into benzene when exposed to common use temperatures and conditions. Defendant has a long history of success, and its brands

<sup>27</sup> H. Erlenmeyer and W. Schoenauer, *Über die thermische Zersetzung von Di-acyl-peroxyden*, HELV. CHIM. ACTA, 19, 338 (1936), <https://onlinelibrary.wiley.com/doi/10.1002/hlca.19360190153> (last visited Feb. 5, 2024).

<sup>28</sup> Benzoyl peroxide is known to thermally decompose to form two molecules of benzoyloxy radicals that can further decompose to benzoic acid or phenyl radicals with liberation of carbon dioxide. The phenyl radicals can then produce benzene. See Shang-Hao Liu et al., *Thermal hazard evaluation of the autocatalytic reaction of benzoyl peroxide using DSC and TAM III*, THERMOCHIMICA ACTA, Volume 605, (2015), Pages 68-76, ISSN 0040-6031, <https://www.sciencedirect.com/science/article/pii/S004060311500057X> (last visited Feb. 5, 2024).



are among the most recognized in the world.

31. Defendant further knew or should have known that specific ingredients derived from hydrocarbons increased the risk the BPO Products would yield benzene.<sup>29</sup> At-risk ingredients include carbomers, mineral spirits, and other petroleum derived substances. These ingredients are red flags for risk of benzene contamination. The FDA published guidance in 2022 urging the industry to reformulate drug products at risk of benzene contamination.<sup>30</sup> The FDA's alert highlighted ingredients made from hydrocarbons, including carbomers (thickening agents), urging drug manufacturers to test products containing them for benzene contamination.<sup>31</sup> Many of the Defendant's Products contain hydrocarbons and carbomers but none have been recalled due to benzene contamination.

32. Defendant knew or should have known through their own research, development, formulation, manufacturing, and testing whether the BPO Products were chemically and physically stable. Defendant was required not only to adequately test the BPO Products for safety and stability before selling them to the public, but also to monitor their internal practices, processes, and specifications to make sure they kept pace with science and emerging methodologies. Defendant knew or should have known from expiration and stability studies examining the "shelf life" of the BPO

---

<sup>29</sup> Food and Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*.

<sup>30</sup> Food and Drug Administration. *Reformulating Drug Products That Contain Carbomers Manufactured With Benzene* (December 27, 2023), <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reformulating-drug-products-contain-carbomers-manufactured-benzene>.

Products, the chemical changes took place because of normal and expected environmental, use, and storage conditions.

33. Defendant knew or should have known the BPO Products would be handled, used, and stored by distributors, sellers, and consumers under various temperatures that affect chemical stability. Defendant knew or should have known the BPO Products would travel by commercial carriers and distributors in varying storage conditions and would be stored by consumers in handbags, backpacks, bathrooms, showers, lockers, and in vehicles during warm months where the BPO Products would be exposed to heat. Defendant knew or should have known consumers would apply the benzene contaminated BPO Products to their faces and bodies and would also use the BPO Products in heated showers as scrubs and washes. Defendant knew or should have known the BPO Products would be used and applied to the skin at normal body temperatures, and elevated temperatures following showers or baths, after physical activity, and after the BPO Products sat in warm temperatures or hot vehicles.

34. These storage, use, and handling conditions were known or should have been known to Defendant before the BPO Products were marketed and sold to public. Defendant knew or should have known the BPO Products degrade to benzene under these conditions exposing consumers to benzene and increasing their risk of cancer. Defendant further knew or should have known that, because of the known degradation of BPO to benzene, their BPO Products were contaminated with benzene by the time

---

<sup>31</sup> *Id.*; see also December 22, 2022 FDA Alert at 1.

they reached consumers, but they sold them to Plaintiff, the Class, the Subclass, and the public anyway, without warning of the contamination, or risk of exposure.

Moreover, the 2–3-year shelf life printed on the BPO Products told consumers they were safe for use for years, when they were not. The levels of benzene in the BPO Products at 2-3 years would be far more than the levels found by the Valisure scientists at 10 days.

**C. DEFENDANT KNEW OR SHOULD HAVE KNOWN BENZENE WAS FOUND IN OTHER CONSUMER PRODUCTS BUT DID NOT TEST THE BPO PRODUCTS**

35. Defendant was aware or should have been aware of benzene contamination in other on-market drug and healthcare products when they sold the BPO Products to Plaintiff, the Class, the Subclass, and the public but did not test the BPO Products for benzene contamination. In 2020, the FDA started working with companies to identify benzene in products, which resulted in product recalls of hand sanitizers, sunscreens, and deodorants. In 2021, an independent chemical analysis by Valisure of hundreds of sunscreens and after-sun care products from 69 brands found 27 percent of the batches had significant levels of benzene above the FDA 2 ppm limit.<sup>32</sup> Johnson and Johnson’s Aveeno and Neutrogena sunscreen lines were among the most benzene contaminated and were recalled.<sup>33</sup> CVS’s private brand after-sun care products were also highly contaminated with benzene, but not recalled by CVS.

---

<sup>32</sup> Valisure Citizen Petition on Benzene in Sunscreen and After-sun Care Products, May 24, 2021.

<sup>33</sup> Press Release. (July 14, 2021), Johnson & Johnson Consumer Inc. *Johnson & Johnson Consumer Inc. Voluntarily Rec of Specific Neutrogena and Aveeno Aerosol Sunscreen Products Due to the Presence of*

The contamination of these consumer products was widely reported around the world. By 2021, Defendant was aware of the benzene contamination issues in many drug and consumer products but continued to advertise and sell the BPO Products without testing them for benzene.

**D. DEFENDANT IGNORED FDA’S BENZENE ALERT TO TEST THEIR BPO PRODUCTS**

36. In 2022, the FDA issued a safety alert warning drug manufacturers of the risk of benzene contamination in certain drug products and drug components. The FDA reiterated the risk benzene exposure poses to public health and the drug manufacturers’ obligations to test drug products under the U.S. Code of Federal Regulations, Title 21:

FDA reminds manufacturers they are required to establish scientifically sound and appropriate specifications and test procedures to assure drug components (active and inactive ingredients) and finished drug products conform to appropriate quality specifications (21 C.F.R. 211.84, 21 C.F.R. 211.160). This includes testing of raw materials and finished batches (21 C.F.R. 211.165) prior to release to ensure they meet appropriate specifications for identity, strength, quality, and purity.<sup>34</sup>

37. The FDA warned drug manufacturers that any drug products or components at risk of benzene contamination should be tested, and any batches with benzene above 2 ppm should not be released to the public.<sup>35</sup> The FDA further warned

---

*Benzene.*

<sup>34</sup> Federal Drug Administration. (Dec. 22, 2022). *FDA Alerts Drug Manufacturers to the Risk of Benzene in Certain Drugs*, 1.

<sup>35</sup> *Id.*, 3.

that, if any drug or drug component was subject to deterioration, drug manufacturers must have re-testing procedures in place to ensure continued purity and stability. The FDA recommended risk assessments to evaluate the possibility of benzene contamination in the drug products or components.<sup>36</sup> If any drug product in circulation was found to have benzene over 2ppm, the FDA directed that drug manufacturers contact the FDA to discuss a voluntarily recall.<sup>37</sup>

38. To date, none of the Defendant's BPO Products have been recalled due to benzene contamination.

**E. RECENT TESTING FOUND COMMON BPO PRODUCTS CONTAIN DANGEROUS LEVELS OF BENZENE IN EXCESS OF REGULATORY LIMITS**

39. Testing by Valisure in 2023 found common acne treatment products formulated with BPO are not only contaminated with benzene but have levels dangerous to public health. Valisure is an accredited independent laboratory who has developed validated analytical methods<sup>38</sup> to test drugs and consumer products to address rising concerns about public safety. Valisure has tested a wide variety of drugs and products for benzene including sunscreens, antiperspirants, hand sanitizers, and dry shampoos. Their work has led to widely publicized product recalls protecting the public from dangerous and carcinogenic consumer products.<sup>39</sup>

---

<sup>36</sup> *Id.*

<sup>37</sup> *Id.*, 2.

<sup>38</sup> Valisure's test methods largely mirror those utilized by FDA's own "Drug Quality Sampling and Testing" ("DQST") Program. Valisure FDA Citizen's Petition at 4.

<sup>39</sup> See Valisure May 24, 2021 Citizen Petition on Benzene in Sunscreen and After-sun Care Products, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-sunscreen>); Valisure's Citizen Petition on Hand Sanitizer Products Containing Benzene Contamination (filed March 24, 2021),

40. In 2023, Valisure tested 175 finished acne treatment products to determine whether any had benzene. Of the 175 products tested, 99 were formulated with BPO, 58 had active ingredients (either individually or in combination) of salicylic acid, sulfur, adapalene, azelaic acid, niacinamide and zinc, and 18 had no drug ingredients.<sup>40</sup> 83 of the BPO Products were purchased over the counter from major retailers and 16 were prescription products purchased from licensed wholesalers.<sup>41</sup> The BPO Products included popular Products: Proactiv 2.5% BPO Cream, Target Up & Up 2.5% BPO Cream, Equate Beauty 10% BPO Cream, Equate BPO Cleanser, Neutrogena 10% BPO Cleanser, Clearasil 10% BPO Cream, CVS Health 10% BPO Face Wash, Walgreens 10% BPO Cream, La Roche Posay BPO Cream, and Clean & Clear 10% BPO Lotion.

41. Valisure used three incubation temperatures to evaluate the effects of common distributor and consumer use, handling, and storage conditions on benzene


---

<https://www.regulations.gov/document/FDA-2021-P-0338-0001>), Valisure's Citizen Petition on Benzene in Sunscreen and After-sun Care Products (filed May 24, 2021), <https://www.regulations.gov/document/FDA-2021-P-0497-0001>), Valisure's Citizen Petition on Benzene in Body Spray Products (filed November 3, 2021, <https://www.regulations.gov/document/FDA-2021-P-1193-0001>), Valisure's Citizen Petition on Benzene in Dry Shampoo Products (filed October 31, 2022), <https://www.regulations.gov/document/FDA-2022-P-2707-0001>) *see also* CNET, Dry Shampoo Recall: What Is Benzene and Which Brands Are Affected <https://www.cnet.com/health/personal-care/dry-shampoo-recall-what-is-benzene-and-which-brands-are-affected/> (identifying 19 types of dry shampoo have been recalled due to benzene content); Ryan Basen, Medpage Today, After Valisure Petition, Ol' Dirty Benzene Forces Another Recall (November 30, 2021), <https://www.medpagetoday.com/special-reports/exclusives/95929> ("After Valisure Petition, Ol' Dirty Benzene Forces Another Recall"); Bruce Y. Lee, Forbes, FDA: P&G Recalls Antiperspirant Sprays Due To Cancer Risk Of Benzene (Nov. 24, 2021), <https://www.forbes.com/sites/brucelee/2021/11/24/fda-pg-recalls-antiperspirants-body-sprays-due-to-cancer-risk-of-benzene/?sh=69cf13c24f32>; *see also* Sandee LaMotte, CNN, Antiperspirant recall: What the finding of a cancer-causing chemical means for you (Dec. 1, 2021), <https://www.cnn.com/2021/12/01/health/deodorants-antiperspirants-recall-benzene-explainer-wellness/index.html>.

<sup>40</sup> *See* Valisure Citizen's Petition on Benzoyl Peroxide (March 4, 2024).

formation. 37°C/98.6°F was used for human body temperature, 50°C/122°F was used to evaluate shelf-life performance as an accelerated stability testing temperature used by the pharmaceutical industry,<sup>42</sup> and 70°C/158°F to model storage in a hot vehicle.<sup>43</sup> The BPO Products were incubated at 37°C for four weeks and 50°C for three weeks and benzene concentration was measured at certain time intervals using GC-MS. Benzene findings were plotted in real time and reported in parts per million (“ppm”). The results below were submitted to the FDA in Valisure’s March 5, 2024 Citizen’s Petition on Benzoyl Peroxide.<sup>44</sup>

4A




<sup>41</sup> *Id.*

<sup>42</sup> Ghimire, Prakash et al., *Guidelines on Stability Studies of Pharmaceutical Products and Shelf-Life Estimation*. INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY AND BIOTECHNOLOGY, (2020). 06. 15-23. 10.38111/ijapb.20200601004.


<sup>43</sup> Grundstein A, Meentemeyer V, Dowd J. *Maximum vehicle cabin temperatures under different meteorological conditions*. Int J Biometeorol. 2009 May;53(3):255-61. doi: 10.1007/s00484-009-0211-x. Epub 2009 Feb 21. PMID: 19234721.

<sup>44</sup> Valisure, LLC, (March 6, 2024), *Valisure Discovers Benzoyl Acne Treatment Products are Unstable and Form Benzene*, <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last visited March 6, 2024).


### 4B



### 4C




### 4D







### 4E




### 4F



### 4G



## 4H



42. Valisure found the BPO formulated products were not chemically stable and yielded benzene at levels well over 2 ppm, the maximum amount allowed in any U.S. regulated drug. Some of the benzene levels were 800 times higher than 2 ppm reaching as high as 1700 ppm.<sup>45</sup> The concentration of BPO in the Products did not influence the benzene levels, e.g., Target's Up & Up BPO Lotion and Proactiv's 10% BPO Cream yielded similar benzene results in the range of 600 ppm. Unexpectedly, Valisure found that benzene vapors leaked from some of the tested Products' packaging contaminating the surrounding air even when the packaging was closed raising concern for additional inhalation exposures.<sup>46</sup>

43. Valisure concluded that all on-market BPO acne formulations are fundamentally unstable and form unacceptably high levels of benzene under normal use, handling, and storage temperatures, but no such evidence was observed for acne

<sup>45</sup> *Id.*

<sup>46</sup> *Id.*

treatment products not formulated with BPO.<sup>47</sup> The finding that additional benzene leaked into the surrounding air from the products' containers means the total consumer benzene exposure would be even more dangerous than the levels reported.

44. Valisure filed a Citizen's Petition on Benzoyl Peroxide on March 5, 2024<sup>48</sup> with the FDA requesting the FDA Commissioner to immediately demand a recall of all BPO Products formulated with BPO and further to require that drug manufacturers do independent chemical verification.<sup>49</sup>

**F. DEFENDANT EXPOSED PLAINTIFF, THE CLASS, AND THE PUBLIC TO BENZENE, A KNOWN HUMAN CARCINOGEN, WITHOUT THEIR KNOWLEDGE**

45. Although benzene has been found in the BPO Products and released into the surrounding air from the packaging, Defendant did not list benzene among the Products' ingredients, on the Products' label or container, or anywhere in their advertising or on their websites. Defendant did not (and still do not) warn that the Products contain benzene, are at risk of benzene contamination, or that the product could cause consumers to be exposed to benzene even when sealed.

46. Benzene is a carcinogen that has been among the most studied toxins over the last 100 years due to its wide use during the industrial revolution, extreme danger, and known ability to cause cancer and death in humans and animals. The

---

<sup>47</sup> *Id.*

<sup>48</sup> As of the date of filing this Class Action, Valisure's FDA Petition is still pending.

<sup>49</sup> Valisure Citizen Petition on Benzene in Benzoyl Peroxide Products (March 5, 2024), <https://www.valisure.com/valisure-newsroom/valisure-detects-benzene-in-benzoyl-peroxide> (last

medical literature linking benzene to blood cancers is vast dating to the 1930s.<sup>50</sup>

Benzene is the foundation component for many chemicals used to make plastics, resins, synthetic fibers, paints, dyes, detergents, drugs, and pesticides. In the past, benzene was widely used as a solvent in industrial paints, paint removers, adhesives, degreasing agents, denatured alcohol, and rubber cements. Benzene use has declined due to the proliferation of worker studies and an ever-growing body of evidence confirming benzene's contribution to blood cancers.

47. Benzene has no known safe level of exposure.<sup>51</sup> Benzene causes central nervous system depression and destroys bone marrow, leading to injury in the hematopoietic system.<sup>52</sup> The International Agency for Research on Cancer (“IARC”) classifies benzene as a “Group 1 Carcinogen” that causes cancer in humans, including acute myelogenous leukemia (“AML”).<sup>53</sup> AML is the signature disease for benzene exposure with rates of AML particularly high in studies of workers exposed to

---

visited March 7, 2024).

<sup>50</sup> See Hamilton A., *Benzene (benzol) poisoning*, ARCH PATHOL, (1931):434-54, 601-37; Hunter FT, *Chronic exposure to benzene (benzol). Part 2: The clinical effects*. J. IND. HYG TOXICOL, (1939):21 (8) 331-54; Mallory TB, et al., *Chronic exposure to benzene (benzol). Part 3: The pathological results*. J. IND. HYG TOXICOL, (1939):21 (8) 355-93; Erf LA, Rhoads CP., *The hematological effects of benzene (benzol) poisoning*. J. IND. HYG TOXICOL, (1939):21 421-35; American Petroleum Institute, *API Toxicological Review: Benzene*, NEW YORK, (1948); Infante PF, Rinsky RA, Wagoner JK, et al., *Leukemia in benzene workers*, LANCET, (1977);2 (8028): 76-78.

<sup>51</sup> Harrison R, Saborit, J., *WHO Guidelines for Indoor Air Quality – Selected Pollutants*, (2010); see also Smith, Martyn T. (2010). *Advances in Understanding Benzene Health Effects and Susceptibility. Annual Review of Public Health.*, (2010) Vol. 31:133-148.

<sup>52</sup> FDA Toxicological Data for Class 1 Solvents, Appendix 4, *Benzene*, <https://www.fda.gov/media/71738/download>.

<sup>53</sup> International Agency for Research on Cancer. *Benzene, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 120*, LYON, France: World Health Organization, (2018).

benzene.<sup>54</sup>

48. Benzene exposure is cumulative and additive. There is no safe level of exposure to benzene, and all exposures constitute some risk in a linear, if not supralinear, and additive fashion.”<sup>55</sup>

49. The Agency for Toxic Substances and Disease Registry’s (“ATSDR”) “Tox Facts” for benzene warns that people can be exposed to benzene vapors from benzene-containing products and that benzene harms the blood marrow, causing leukemia and anemia, and affects the immune system leaving victims vulnerable to infection.<sup>56</sup>

50. According to the FDA, benzene in small amounts over long periods of time can decrease the formation of blood cells and long-term exposure through inhalation, oral intake, and skin absorption may result in cancers such as leukemia and other blood disorders.<sup>57</sup>

51. Benzene is a major industrial chemical made from coal and oil that is heavily regulated by the EPA as an important environmental pollutant that negatively affects the soil, air, and groundwater. Waste and air emissions containing benzene are considered hazardous waste. The coal, oil, paint, and chemical industries are heavily

---

<sup>54</sup> American Cancer Association, *Benzene and Cancer Risk*, <https://www.cancer.org/cancer/risk-prevention/chemicals/benzene.html> (last visited October 20, 2023).

<sup>55</sup> Smith, Martyn T., *Annual Review of Public Health*, ADVANCES IN UNDERSTANDING BENZENE HEALTH EFFECTS AND SUSCEPTIBILITY (2010) Vol. 31:133-148.

<sup>56</sup> Agency for Toxic Substances and Disease Registry, *Benzene – Tox Facts*, CAS # 71-43-2.

<sup>57</sup> Federal Drug Administration. (June 9, 2022). *Frequently Asked Questions*: <https://www.fda.gov/drugs/drug-safety-and-availability/frequently-asked-questions-benzene-contamination-drugs>.

regulated due to the emission of carcinogens including benzene from refining and other industries processes involving benzene and benzene byproducts, which can end up in the air, water, and food supply.

52. Benzene is heavily regulated to protect public health and should not be in drug products, especially ones such as acne treatment that are used daily by children and teenagers for many years. The FDA drug guidelines specify that benzene must not be used to make drugs products because of the unacceptable toxicity and deleterious environmental effects.<sup>58</sup> The FDA allows one limited exception – where the use of benzene in a drug product is unavoidable to produce a drug product with a significant therapeutic advance. In that instance, benzene must be restricted to two parts per million (ppm).<sup>59</sup> Defendant’s BPO Products do not meet this rare exception.

53. Benzene is heavily regulated in the workplace. The U.S. Occupational Safety and Health Administration (“OSHA”) set an eight-hour exposure standard of 1 ppm.<sup>60</sup> The National Institute for Occupational Safety and Health (“NIOSH”) established a recommended exposure level (REL) of 0.1 ppm (15-minute ceiling limit). Subsequent exposure studies known as the “China studies” confirmed cancer at levels below 1 ppm.<sup>61</sup> The benzene levels created from Defendant’s BPO Products

---

<sup>58</sup> Food and Drug Administration, *Q3C – Tables and Lists Guidance for Industry*, <https://www.fda.gov/media/71737/download> (last visited September 26, 2023).

<sup>59</sup> *Id.*

<sup>60</sup> OSHA. Occupational exposure to benzene: Final rule. Fed. Reg. 1987;52-34460-578.

<sup>61</sup> See Lan Q, Zhang L et al., *Hematotoxicity in Workers Exposed to Low Levels of Benzene*, SCIENCE, (December 3, 2004); Costa-Amaral I, V. B. L., *Environmental Assessment and Evaluation of Oxidative Stress and Genotoxicity Biomarkers Related to Chronic Occupational Exposure to Benzene*, INT J ENVIRON RES PUBLIC HEALTH, (2019) Jun; 16(12): 2240.

are many times higher than the levels reported in these worker studies and the acceptable limits set by regulators.

54. Benzene can also pass from the mother's blood to a developing fetus causing the baby to be exposed to benzene.<sup>62</sup> Animal studies have shown low birth weights, delayed bone formation, and damage to the bone marrow of developing offspring when pregnant animals breathed benzene.<sup>63</sup>

55. Plaintiff, the Class, Subclasses were exposed to benzene from the BPO Products by inhalation and dermal absorption. Benzene can be absorbed into the body via inhalation, skin absorption, ingestion, and/or eye contact.<sup>64</sup> Plaintiff and the Class applied the BPO Products to areas of the skin including the face, neck, chest, and back one to three times per day and used the BPO Products as washes or scrubs in heated showers. Plaintiff and the Class were also exposed to benzene leaked from contaminated BPO Products.

**G. DEFENDANT PUBLICLY AFFIRMED IT WAS FOUNDED ON “SCIENCE AND SAFETY” BUT CONCEALED ITS FAILURE TO TEST THE BPO PRODUCTS FOR SAFETY**

56. Defendant's BPO Products degrade to benzene, during normal and expected handling, use, or storage but Defendant did not warn Plaintiff, the Class, the Subclass, and the public about benzene contamination or the health risks of exposure.

---

<sup>62</sup> *Id.*

<sup>63</sup> *Id.*

<sup>64</sup> Centers for Disease Control and Prevention, *The National Institute for Occupational Safety and Health Pocket Guide to Chemical Hazards, Benzene Exposure Limits*, <https://www.cdc.gov/niosh/npg/npgd0049.html>.

Instead, Defendant made broad sweeping claims that the BPO Products were safe, researched, tested, validated, backed by science, and approved by board certified dermatologists.

57. Defendant assured Plaintiff, the Class, and Subclass members the formulation charter for each L’Oreal USA, Inc. product “goes far beyond international cosmetics regulations.”<sup>65</sup> The company continued, “we are strict because we care, and we embark on each step of our development process with precision and efficacy. Always backed by the ever-developing advancements in dermatological research.”<sup>66</sup>

58. Defendant’s misrepresentations and omissions misled Plaintiff, the Class, the Subclass, and the public regarding the safety, stability, and quality of the BPO Products. Defendant’s broad claims of safety in their marketing, social media, and on websites gave Plaintiff, the Class, the Subclass, and the public a false sense of safety leading them to believe the BPO Products were safe. Defendant made these statements uniformly to Plaintiff, the Class, the Subclass, and the public, while shirking their responsibility to do adequate and meaningful testing before selling them to the public. Defendant’s statements and affirmations were false, misleading, unsubstantiated, and blatantly deceptive.

---

<sup>65</sup> La Roche-Posay, *Strict Safety and Formula Charter*, <https://www.larouche-posay.us/our-story.html> (last visited October 10, 2023).

<sup>66</sup> *Id.*



**H. DEFENDANT DID NOT WARN PLAINTIFF, THE CLASS, AND SUBCLASSES THE BPO PRODUCTS WERE AT RISK OF BENZENE CONTAMINATION**

59. Defendant represented to the Plaintiff, the Class, the Subclasses, and the public, that their BPO Products had only the ingredients listed on the label and package and product information descriptions online but none of them identified benzene anywhere on the Products' label, container, packaging, or in advertising or their websites.

60. Defendant's statements about the BPO Products' ingredients were false, deceptive, and misleading. Defendant's statements were meant to convey to Plaintiff, the Class, the Subclasses, and the public the Products were safe and did not contain carcinogens such as benzene. Defendant made these statements and omitted benzene from all advertising, labeling, and packaging when they knew or should have known the statements were false, misleading, and deceptive. Reasonable consumers, relying on Defendant's statements reasonably believed the BPO Products were safe and did not contain benzene.

**I. DEFENDANT DIRECTLY MARKETED BPO PRODUCTS TO CHILDREN AND TEENAGERS WHEN THEY KNEW OR SHOULD HAVE KNOW OF THE RISK OF BENZENE CONTAMINATION**

61. Defendant's BPO Products are widely used by children and teenagers as a standalone treatment or in combination with other BPO Products. Defendant knew that adolescents are the largest users with users as young as 7-10 years old. Defendant

recommended that consumers, including children, use the BPO Products one to three times a day, over many months or longer for persistent acne. Defendant knew that some consumers would use the BPO Products for many years starting in their teens. There is no cure for acne. Defendant knew that consumers with chronic acne would use their BPO Products several times a day throughout their lifetime.

62. Defendant aggressively marketed the BPO Products directly to children and teenagers knowing, or they should have known, the BPO Products degrade to benzene under normal use and storage conditions. Defendant's online and print advertisements featured teenagers and were meant to attract teens and pre-teens, and appeal to their preferences, activities, and interests.

63. Defendant said teenagers struggling with acne should look for acne treatment products formulated with "benzoyl peroxide."<sup>67</sup> Defendant's proudly confirmed the key ingredient in La Roche-Posay Effaclar Duo Acne Spot Treatment was 5.5% of Benzoyl Peroxide.<sup>68</sup> Defendant bragged its benzoyl peroxide was "milled to a consistent small size allowing for deep penetration into the pores" making it "an ideal choice for those concerned with red, raised acne blemishes and pimples."<sup>69</sup> Defendant also said the BPO Product was recommended by a board certified

---

<sup>67</sup> La Roche-Posay, *Teenage Acne Causes and Treatment*, <https://www.laroche-posay.us/skincare-tips-and-advice/acne-oily-skin/teenage-acne-causes-and-treatments.html> (last visited October 17, 2023).

<sup>68</sup> La Roche-Posay, *Our Products, Effaclar Duo Acne Spot Treatment*, <https://www.laroche-posay.us/our-products/acne-oily-skin/spot-treatment/effaclar-duo-acne-spot-treatment-effaclarduoacnespottreatment.html#tab=ingredients> (last visited October 17, 2023).

<sup>69</sup> *Id.*

dermatologist.<sup>70</sup>

64. Defendant's marketing of the BPO Products without mentioning benzene, the risk of benzene exposure, or testing for benzene was misleading, fraudulent, deceptive, and dangerous.

## V. PUNITIVE DAMAGES ALLEGATIONS

65. Defendant's conduct was done with malice and reckless disregard for human life. Defendant knew the BPO Products degraded to benzene when exposed to heat under normal consumer use, handling, and storage conditions. Defendant further knew that benzene is a known human carcinogen that is not supposed to be in the BPO Products due to the grave risk of harm to consumers. Defendant disregarded this information and the known risks of benzene exposure and deliberately omitted benzene from the list of ingredients, the BPO Products' labels, and their social media and websites where information about the BPO Products is found. Defendant consciously and deliberately crafted the BPO Products' marketing, labels, packaging, containers, and warnings intending to mislead Plaintiff, the Class, the Subclasses, and the public, and lead them to believe the BPO Products were safe and carcinogen-free.

66. Defendant marketed themselves as expert drug formulators, researchers, and merchandisers skilled in developing safe and reliable products while withholding material health and safety information Defendant knew were essential to informed consumer decision making. Defendant knew that, by their conduct, they were robbing

---

<sup>70</sup> *Id.*

Plaintiff, the Class, the Subclasses, and the public of their right to choose safe products.

67. Defendant was on notice of benzene findings in their own and other consumer and drug products leading to widely publicized recalls. Defendant was on notice of the FDA's concerns of benzene contamination in drug and consumer products and received the FDA's 2022 directive to test Products for benzene contamination. Defendant disregarded these notices and continued to market and sell the BPO Products without testing them for benzene.

68. Defendant knew its decisions and chosen course of conduct was risky and would cause consumers to be exposed to benzene. Defendant's conduct was not by accident, but was deliberate, calculated, and informed. Defendant knew they could sell more BPO Products and earn more money by concealing material human health and safety information. Defendant further knew that testing the BPO Products for benzene would yield findings of benzene requiring recalls and/or a shutdown of production causing significant losses of income. Defendant's goals were met not only because of their false and deceptive advertising, labeling, and packaging, but through a comprehensive scheme of aggressive marketing and image branding leading consumers to believe they were acne treatment experts dedicated to drug research, development, and safety and using only the safest ingredients and formulations that would remain pure and stable until the designated end. Defendant's conduct and concealment of material health information was done to further their own monetary

gain and with conscious disregard of the Plaintiff's, the Class, the Subclasses, and the public's right to choose safe products. Defendant's conduct was intentional, calculated, blatantly deceptive, unscrupulous, and offensive to consumer health and public policy. To redress the harms caused by Defendant's conduct, Plaintiff, on behalf herself, the Class, and Subclasses, seek punitive damages against the Defendant.

## **VI. PLAINTIFF SPECIFIC ALLEGATIONS**

69. Plaintiff Jennifer Snow is a Hawaii resident who places a high priority on health and safety, and on the adverse health consequences of exposure to carcinogens such as benzene. In shopping for acne drug products for her skin and face, Plaintiff Jennifer Snow was particularly concerned about product reviews and cost efficiency. Based on the statements made by Defendant, its widely recognized name, and lack of information that the Products contained carcinogens such as benzene, Plaintiff believed Defendant's Products were safe to put on her skin. Defendant's representations and omissions of human health and safety information were material to Plaintiff.

70. Plaintiff Snow bought Defendant's La Roche-Posay Effaclar Duo Dual Acne Treatment and used it from May 2023 to October 2023 for pimples and to help reduce acne blemishes on the spot. Plaintiff was unaware when she bought the BPO Product that it was contaminated with benzene or that it could degrade to benzene. Had Defendant been truthful and told Plaintiff she would be exposed to benzene

and/or be at increased risk of cancer, she would not have purchased La Roche-Posay Effaclar Duo Dual Acne Treatment.

71. Plaintiff Snow suffered an ascertainable economic loss because of Defendant's statements and misrepresentations and bought the BPO Product she would not have bought but for Defendant's statements and misrepresentations.

## **VII. CLASS ACTION ALLEGATIONS**

72. Plaintiff brings this case on behalf of herself, and all others similarly situated as a Class Action under Rule 23 of the Federal Rules of Civil Procedure. Plaintiff seeks to represent a National Class of consumers who bought the Products, and State Subclasses of consumers from the states identified below. Excluded from this Class are Defendant, their employees, co-conspirators, officers, directors, legal representatives, heirs, successors, and affiliated companies; Class counsel and their employees; and judicial officers and their immediate families as court staff assigned to the case.

73. The Class does not seek damages for physical injuries, although Plaintiff was physically harmed by being exposed to benzene.

74. The Class will include a National Class to include all persons who bought for use, and not resale, the Products within the United States.

75. The State Subclasses will include all persons who bought for use, and not resale, the Products within California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Ohio, Pennsylvania, Rhode Island, and

Washington.

76. This action has been brought and may be properly maintained as a Class Action under Rule 23 of the Federal Rules of Civil Procedure because there is a well-defined community of interest and the proposed Class meets the class action requirements under Rule 23 of numerosity, commonality, typicality, and adequacy of representation.

77. Defendant engaged in a common course of conduct giving rise to the legal rights sought to be enforced by Plaintiff, on behalf of herself, and the other Class members. Similar or identical statutory and common law violations, business practices, and injuries are involved.

78. **Numerosity.** Plaintiff believes there are millions of Class members throughout the United States, and there are tens of thousands of Subclass members in each of the listed states, making the Class and state Subclasses so numerous and geographically dispersed that joinder of all members is inconvenient and impracticable.

79. **Commonality.** There are questions of law and fact common to all Class and Subclass members that predominate over questions which affect only individual Class members. All Class and Subclass members were deceived and misled by Defendant through the same advertising, online representations, labeling, and packaging, which do not mention benzene and misrepresent the characteristics, ingredients, and safety of the BPO Products. All Class and Subclass members bought

Defendant's BPO Products and have suffered an economic loss because of Defendant's deceptions and omissions. Thus, there is a well-defined community of interest in the questions of law and facts common to all Class and Subclass members.

Other common questions of law and fact in this dispute include, without limitation:

- a. Whether Defendant's BPO Products degrade to benzene under common distributor and consumer handling, use, and storage conditions.
- b. Whether Defendant tested the BPO Products for benzene before selling them to Plaintiff, the Class, and the public.
- c. When Defendant knew or should have known the BPO Products degraded to benzene.
- d. When Defendant knew or should have known the BPO Products contain benzene.
- e. Whether Defendant's advertising omitting benzene was deceptive, fraudulent, or unfair.
- f. Whether Defendant's advertising omitting benzene was likely to deceive reasonable consumers.
- g. Whether Defendant's conduct violated California's Unfair Competition Law, Bus. & Prof. Code § 17200 *et seq.*
- h. Whether Defendant's conduct violated California consumer protection laws.
- i. Whether Defendant's conduct violated Connecticut consumer protection laws.
- j. Whether Defendant's conduct violated Hawaii consumer protection laws.
- k. Whether Defendant's conduct violated Illinois consumer protection laws.
- l. Whether Defendant's conduct violated Massachusetts consumer protection laws including Mass. Gen. Laws Ann. Ch. 93A, § 1 *et seq.*



- m. Whether Defendant's conduct violated Maryland consumer protection laws.
- n. Whether Defendant's conduct violated Missouri consumer protection laws including Mo. Rev. Stat. § 407, *et seq.*
- o. Whether Defendant's conduct violated Nevada consumer protection laws including Deceptive Trade Practice Act, NEV. REV. STATUTES, Title 52, Chapter 598 *et seq.*
- p. Whether Defendant's conduct violated New York consumer protection laws including New York Deceptive Trade Practices Law, NY Gen. Bus. §349(a) and NY Gen. Bus. §§ 350 *et seq.*
- q. Whether Defendant's conduct violated Ohio's deceptive trade practices act and consumer protection laws.
- r. Whether Defendant's conduct violated Pennsylvania consumer protection laws.
- s. Whether Defendant's conduct violated Rhode Island consumer protection laws.
- t. Whether Defendant's conduct violated Washington's consumer protection laws.
- u. Whether Defendant breached the express and implied warranties they made about the BPO Products.
- v. Whether Defendant was unjustly enriched by the Plaintiff, the proposed Class, and Subclasses members' purchase of the BPO Products.
- w. Whether the Plaintiff, the proposed Class, and Subclasses have been injured and if so, what is the proper measure of damages.
- x. Whether the Plaintiff, the proposed Class, and Subclasses have the right to economic damages including compensatory, exemplary, and statutory remedies for Defendant's misconduct.

- y. Whether the Plaintiff, the proposed Class, and Subclasses have the right to injunctive, declaratory, or other equitable relief and attorneys' fees.

80. **Typicality.** Plaintiff's claims are typical of the claims of the Class and Subclasses because the claims arise from the same course of misconduct by Defendant, *i.e.*, Defendant's false and misleading advertising and their failure to disclose benzene in the Products. The Plaintiff, and all Class and Subclass members were all exposed to the same uniform and consistent advertising, labeling, and packaging statements Defendant made about the Products. Because of the Defendant's misconduct, Plaintiff, like all Class members, was damaged and has incurred economic loss because of buying the Products believed to be safe. The claims of the Plaintiff are typical of Class members.

81. **Adequacy.** The Plaintiff will fairly and adequately represent and protect the interests of all Class and Subclass members. Plaintiff has no interests antagonistic to the Class or Subclass members. Plaintiff hired attorneys experienced in the prosecution of consumer Class Actions and Plaintiff intends to prosecute this action vigorously. Plaintiff anticipates no difficulty in the management of this litigation as a Class Action.

82. Finally, this Class Action is proper under Rule 23(b) because, under these facts, a Class Action is superior to other methods and is the most efficient method for the fair and efficient adjudication of the dispute. The Class and Subclass members have all suffered economic damages because of Defendant's deceptive trade practices,

false advertising, and omissions of material health and safety information. Because of the nature of the individual Class and Subclass members' claims and the cost of the Products, few, if any individuals, would seek legal redress against Defendant because the costs of litigation would far exceed any potential economic recovery. Absent a Class Action, individuals will continue to suffer economic losses for which they would have no remedy, and Defendant will unjustly continue their misconduct with no accountability while retaining the profits of their ill-gotten gains. Even if separate cases could be brought by individuals, the resulting multiplicity of lawsuits would cause undue hardship, burden, and expense for the Court and the litigants, as well as create a risk of inconsistent rulings across the country, which might be dispositive of the interests of individuals who are not parties. A Class Action furthers the important public interest of containing legal expenses, efficiently resolving many claims with common facts in a single forum simultaneously, and without unnecessary duplication of effort and drain on critical judicial resources. The Class Action method presents far fewer management difficulties than individual cases filed nationwide and provides the benefit of comprehensive supervision by a single court.

## VIII. CAUSES OF ACTION

### A. VIOLATION OF CALIFORNIA'S UNFAIR COMPETITION LAW BUS. & PROF. CODE § 17200 *et seq.*, on *Behalf of the California Subclass*

83. Plaintiff realleges and incorporates all other paragraphs in this Class

Action Complaint and further allege:

84. Plaintiff brings this cause of action on behalf of herself, and all members of the Nationwide Class, and the California Subclass, all of whom are similarly situated consumers.

85. California's Unfair Competition Law, CAL. BUS. & PROF. CODE § 17200, *et seq.*, prohibits "unlawful, unfair, or fraudulent business act or practices" and "unfair, deceptive, untrue or misleading advertising." Defendant misrepresented their Products in advertising, labels, and containers and misled Plaintiff, the Class and Subclass, and the public about the ingredients, characteristics, purity, quality, approval, and safety of the Products. Defendant led Plaintiff, the Class, and Subclass, and the public to believe the Products were safe.

86. Defendant's advertising, online representations, labeling, and packaging of the Products were misleading, fraudulent, and deceptive. Defendant knew through the Products' development, formulation, research, and pre-sale safety and stability testing, the Products were not chemically and physically stable when exposed to common temperature conditions. Defendant knew or should have known the Products formulated benzene under normal and expected consumer use, handling, and storage conditions, and that consumers would be exposed to benzene. Defendant were specifically reminded by the FDA of their obligation to ensure the safety and quality of their Products, including testing them for benzene before selling them to the public, but shirked their duties and continued to market and sell the Products without substantiating their safety, or warning Plaintiff, the Class, and the public about

benzene.

87. Defendant omitted material health and safety information, *e.g.*, benzene, from the Products' advertising, label, container, and warnings. Defendant did not tell Plaintiff and the Class members they would be exposed to benzene, a human carcinogen, during normal and expected handling, use and storage of the Products, even with the Products' container closed.

88. Defendant's acts and omissions were likely to deceive reasonable consumers and the public. Reasonable consumers expect to be told about all ingredients in Products. Reasonable consumers further expect that carcinogens in the Products be disclosed. Reasonable consumers further expect that on market drugs to be free of carcinogens, unless told otherwise. Benzene in a widely marketed drug product used by children, teens, and the public is material health information reasonable consumers expect to be told.

89. Had Defendant been truthful in their advertising, labeling, packaging, and online statements about benzene in the Products, or the risk of contamination, and the risk of cancer, Plaintiff and the Class members would not have bought the Products.

90. Defendant's acts, omissions, and concealment of material health and safety information are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the Products to the public without telling the public about benzene in the Products, or the risk of contamination, and the risk of cancer.

Defendant continued to market themselves as responsible drug manufacturers and

sellers who sell safe products when they have not tested the Products for benzene or quantified the levels of benzene formed in the Products during normal and expected storage conditions.

91. Defendant engaged in these deceptive practices for significant financial gain, which is unfair, unreasonably dangerous to Plaintiff, the Class, and California Subclass members, and not outweighed by any benefit. Omitting and concealing material human health and safety information such as benzene in the Product and the consumers' risk of cancer from the Products is unethical, unscrupulous, and offensive.

92. Plaintiff, on behalf of herself, and all members of the Nationwide Class, and the California Subclass suffered ascertainable economic losses because of Defendant's misconduct because he bought the Products, he otherwise would not have bought but for Defendant's misrepresentations and affirmations of safety.

93. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and Subclass members, seeks recovery of their economic damages, attorneys' fees, restitution, and all other relief allowable under CAL. BUS. & PROF. CODE § 17200, *et seq.*, including an injunction to enjoin Defendant from continuing their fraudulent and deceptive business practices. The damages sought are ascertainable, uniform to the Class and can be measured and returned to the Class members.

**B. VIOLATION OF CALIFORNIA’S CONSUMER LEGAL REMEDIES ACT, CAL. CIV. CODE § 1750, *et seq.*, on Behalf of the California Subclass**

94. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further allege:

95. Plaintiff brings this cause of action on behalf of herself, and all Class California Subclass members, all of whom are similarly situated consumers within the meaning of CAL. CIV. CODE § 1781.

96. Defendant’s acts and omissions violated California’s Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived by advertisers, distributors, and sellers like the Defendant. Other Defendant regularly transact business in California, including in this District, and have engaged in misconduct that has and had a direct, substantial, foreseeable, and intended effect of injuring people in California, and in this District.

97. California’s Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq. prohibits* unfair methods of competition and unfair or deceptive acts or practices in connection with the sale of consumer goods. Defendant violated several prohibitions of CIV. CODE § 1750(a).

98. Defendant violated CAL. CIV. CODE § 1750(a)(2) by representing the source, sponsorship, and approval, of the Products, *e.g.*, the Products were backed by sound scientific principles, that Defendant met its obligations to conduct adequate and meaningful quality and safety testing before selling the Products to the public, and

represented the Products only contained the ingredients listed, and were free of carcinogens.

99. Defendant violated CAL. CIV. CODE § 1750(a)(3) by representing the affiliation, connection, or association with, or certification by, another *e.g.*, the Products were approved by dermatologists and manufactured in conformity with current good manufacturing practices.

100. Defendant violated CAL. CIV. CODE § 1750 (a)(4) by using deceptive representations, *e.g.*, the Products were safe, validated, and supported by the latest research, and free of carcinogens such as benzene.

101. Defendant violated CAL. CIV. CODE § 1750(a)(5) by representing the Products have characteristics, ingredients, uses, or benefits, which they do not, *e.g.*, misleading Plaintiff and the Class members the Products only contained the listed ingredients, did not contain benzene, and did not increase the risk of the consumers' risk of cancer.

102. Defendant violated CAL. CIV. CODE § 1750(a)(6) by representing the Products were not deteriorated unreasonably or altered *e.g.*, the Products were pure and had not degraded or formed benzene.

103. Defendant violated CAL. CIV. CODE § 1750(a)(7) by representing the Products were pure and of a particular standard or quality, when they are not.

104. Defendant violated CAL. CIV. CODE § 1750(a)(9) by advertising the Products with the intent not to sell them as advertised, *e.g.*, the Products were of pure



quality, safe, made in conformity with current good manufacturing practices, and not adulterated.

105. Had Defendant been truthful in their advertising, labeling, packaging, warnings, and online statements about benzene in the Products and the risk of cancer, Plaintiff and the Class members would not have bought the Products. Benzene, a human carcinogen, in a widely marketed and available consumer drug product, is material health and safety information Defendant knew Plaintiff, the Class members, and the public would want to know. The Defendant's omission of this material information was common to all Class and Subclass members and made to all Class and Subclass members uniformly through common advertising, online representations, labeling, and packaging.

106. Defendant's acts, omissions, and concealment of material health and safety information are ongoing and continuing to cause harm. Defendant continued to market, advertise, and sell the Products to the public without telling the public about benzene in the Products and the risk of cancer. Defendant continued to market themselves as responsible drug manufacturers and sellers who sell safe products when they have not quantified the levels of benzene in and created in the Products during normal and expected storage conditions.

107. Defendant engaged in these deceptive practices for significant financial gain, which is unfair, unreasonably dangerous to Plaintiff, the Class and Subclass members, and not outweighed by any benefit. Omitting and concealing material

human health and safety information such as the consumers' risk of cancer from exposure to the Products is unethical, unscrupulous, and offensive.

108. Plaintiff, on behalf of herself, and all Class California Subclass members suffered ascertainable economic losses because of Defendant's misconduct because he bought the Products, he otherwise would not have but for Defendant's misrepresentations.

109. Because of Defendant's misconduct, Plaintiff, on behalf of herself and the Class and Subclass members, seeks recovery of their economic damages, attorneys' fees, punitive damages, restitution, and all other relief allowable under CAL. CIV. CODE § 1750, *et seq.*, including an injunction to enjoin Defendant from continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the Class and Subclass and can be measured and returned to the Class and Subclass members.

**C. FALSE ADVERTISING UNDER VARIOUS STATE STATUTES,  
on Behalf of the California, Hawaii, and New York Subclasses**

110. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

111. Plaintiff brings this cause of action on behalf of herself, and all members of the California, Hawaii, and New York Subclasses, all of whom are similarly situated consumers.

112. Defendant develops, manufactures, tests, markets, and sells the BPO Products throughout the United States. Defendant knew through the Products' development, formulation, and testing, the Products are not chemically stable when exposed to certain expected and normal environmental and storage conditions and can form benzene, as a toxic byproduct. Despite this knowledge, Defendant did not mention benzene in the Products' advertising, ingredient list, label, container, or warnings. Defendant did not tell Plaintiff, and the Subclass members they would be exposed to benzene, a human carcinogen, during normal and expected handling, use and storage of the Products, even with the Products' containers closed.

113. Benzene, a human carcinogen, in a widely marketed and available consumer drug product, is material health and safety information Defendant knew Plaintiff, the Subclass members, and the public would want to know. Defendant not only omitted this material human health and safety information from advertising, online representations, blogs, labeling, packaging, and warnings, but Defendant aggressively marketed themselves as drug experts, innovators, researchers, market leaders, and companies committed to consumer safety who devote substantial resources to drug research and development. Defendant's affirmations of safety, responsibility and concern for consumers misled Plaintiff, and the Class members, leading them to believe the Products were tested, verified, and safe. Defendant further marketed the Products touting the approval of dermatologists, who were not aware of the presence of benzene in the Products and of Defendant refusal to conduct adequate

and meaningful testing before marketing and selling the Products to the public and following the FDA's 2022 alert to specifically look for benzene.

114. Defendant's acts and omissions constitute false advertising. Defendant advertised the Products with the intent not to sell them as advertised. Reasonable consumers, including Plaintiff and the Class and Subclass members, exposed to Defendant advertising would believe the Products were safe, verified, and free of benzene.

115. Defendant's false and misleading advertising violated California's False Advertising Law, Bus. & Prof. Code § 17500 *et seq.*, which prohibits Defendant from disseminating statements "which are untrue or misleading, and which are known, or which by the exercise of reasonable care should be known, to be untrue or misleading." Defendant knew or should have known the Products formed benzene under normal, handling, use, and storage conditions but did not disclose this to Plaintiff and the Subclass members. Defendant knew through the Products' development, formulation, research, and testing, the Products were not chemically stable when exposed to certain normal and expected environmental conditions. Defendant knew Plaintiff and the Subclass members, and consumers would be exposed to benzene in the Products, even with the Products' original packaging closed.

116. Defendant's false and misleading advertising violated Hawaii's False Advertising Law, HI REV. STAT. § 708-871. Defendant knowingly or recklessly made

false and misleading statements in the Products' advertising to the public.<sup>71</sup>

Defendant further advertised the Products with the intent not to sell them as advertised and misrepresented the ingredients, quality, purity, safety, and character of the Products.

117. Defendant's false and misleading advertising violated New York's General Business Law § 350 *et seq.* ("GBL § 350"), which prohibits "[f]alse advertising in the misconduct of any business, trade or commerce or in the furnishing of any service" in New York. Under GBL § 350, "false advertising" includes "advertising, including labeling, of a commodity . . . if such advertising is misleading in a material respect." Defendant violated GBL § 350 by advertising and selling the Products without disclosing material health and safety information, *e.g.*, benzene and the consumers risk of cancer from benzene. Defendant's false and misleading advertising was directed at consumers, the New York Subclass members, and the public, and caused consumer injury and harm to the public interest.

118. Had Defendant been truthful in their advertising, online representations, labeling, and packaging about benzene, Plaintiff and the Subclass members would not have bought the Products.

---

<sup>71</sup> HI REV STAT § 708-871, False Advertising: (1) A person commits the offense of false advertising if, in connection with the promotion of the sale of property or services, the person knowingly or recklessly makes or causes to be made a false or misleading statement in any advertisement addressed to the public or to a substantial number of persons. (2) "Misleading statement" includes an offer to sell property or services if the offeror does not intend to sell or provide the advertised property or services: (a) At the price equal to or lower

119. Plaintiff on behalf of herself, and all members of the California, Hawaii, and New York Subclasses suffered ascertainable economic losses because of Defendant's misconduct because they bought the Products, they otherwise would not have but for Defendant's material misrepresentations.

120. Because of Defendant's misconduct, Plaintiff, on behalf of herself, and the California, Hawaii, and New York Subclass members, seeks recovery of their economic damages, attorneys' fees, punitive damages, restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from continuing their fraudulent business practices. The damages sought are ascertainable, uniform to the Subclasses and can be measured and returned to the Subclass members.

**D. DECEPTIVE TRADE PRACTICES UNDER VARIOUS STATE STATUTES, on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses**

121. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

122. Plaintiff brings this cause of action on behalf of herself, and all members of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

123. Defendant's acts and omissions constitute deceptive business practices in violation of state deceptive trade practices laws.

124. Defendant represented the BPO Products had characteristics, uses, and benefits, they did not, *e.g.*, Defendant represented the BPO Products were pure, of good quality, safe, and only contained the ingredients disclosed.

125. Defendant represented the BPO Products were not deteriorated or altered, when they knew, or should have known, the BPO Products degraded to benzene under normal and expected use, handling, and storage conditions.

126. Defendant represented the BPO Products contained only the ingredients listed on Defendant's websites, advertising, labels, and containers. Defendant did not disclose to Plaintiff, the Subclass members, and the public that the BPO Products were at risk of benzene contamination.

127. Defendant advertised the BPO Products with the intent not to sell them as advertised.

128. Defendant's acts and omissions violated California's Consumer Legal Remedies Act, CAL. CIV. CODE § 1750, *et seq.*, enacted to protect consumers from being victimized and deceived by advertisers, distributors, and sellers like the Defendant.

129. Defendant's acts and omissions violated *Connecticut* Unfair Trade Practices Act, CONN. GEN STAT. ANN., § 42- 110, *et seq.*, which broadly prohibits

Defendant from engaging in unfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce such as those committed by Defendant and alleged in this Class Action.

130. Defendant's acts and omissions violated Hawaii's Uniform Deceptive Trade Practice Act, HAW. REV. STAT. §481-A3 because Defendant: (1) caused the likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2) represented the Products had characteristics, ingredients, or benefits, they did not; (3) represented the Products were not deteriorated or altered, when they were; (4) represented the Products were of a particular standard or quality when they were not; and (5) advertised the Products with the intent not to sell them as advertised.

131. Defendant's acts and omissions violated Illinois' Consumer Fraud and Deceptive Business Practices Act, 815 ILCS 505/1 *et seq.* Defendant's used deception, fraud, false pretense, false promises, and omitted material health and safety information about the Products' degradation to benzene, and/or contamination with benzene, which Defendant intended the Illinois Subclass members to rely upon.

132. Defendant's acts and omissions violated Maryland's Unfair or Deceptive Trade Practices Act, MD. COM. CODE, Title 13, Subtitle 3, §13-301 because Defendant: (1) represented the Products had characteristics, ingredients, uses, and benefits, they did not; (2) represented the Products were not deteriorated or altered, when they were; (3) represented the Products were of a particular standard or quality,



when they were not. Defendant's representations about the Products' ingredients, and omission of benzene were misleading, deceptive, incomplete, and not truthful in violation of Maryland's Unfair or Deceptive Trade Practices Act.

133. Defendant's acts and omissions violated Massachusetts consumer protection law, MASS. GEN. LAWS ANN. Ch. 93A, § 1 *et seq.*, which broadly prohibits unfair and deceptive trade practices such as those committed by Defendant and alleged in this Class Action.

134. Defendant's acts and omissions violated the Missouri Merchandising Practices Act, MO. REV. STAT. § 407, *et seq.*, which prohibits the use of deception, fraud, misrepresentations, or unfair practices by a business, *e.g.*, marketing Products as safe, approved, tested, and only containing the listed ingredients. Missouri's law further prohibits the suppression or omission of material facts such as the Products' degradation to benzene.

135. Defendant's acts and omissions violated N.Y. GEN. BUS. LAW § 349, which prohibits Defendant from engaging in deceptive, unfair, and misleading acts and practices such as those committed by Defendant and alleged in this Class Action. Defendant's misrepresentations and omissions caused consumer injury and harm to the public interests of protecting public health and the public's right to know about any harmful constituents in the Products.

136. Defendant's acts and omissions violate Nevada Deceptive Trade Practice Act, NEV. REV. STATUTES, Title 52, Chapter 598 *et seq.* which prohibits Defendant from making false statements about their Products and advertising the Products without the intent to sell them as advertised.

137. Defendant's acts and omissions acts and omissions violated Ohio's Consumer Sales Practices Act, OHIO REV. CODE ANN. § 1345.01, *et seq.* which prohibits sales practices that are deceptive, unfair, or unconscionable, and Ohio's Deceptive Trade Practices Act, OHIO REV. CODE ANN. § 4165 *et seq.*

138. Defendant's acts and omissions violated Pennsylvania's Unfair Trade Practices and Consumer Protection Law, 73 P.S. §§201-1 *et seq.* because Defendant: (1) caused the likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2) used deceptive representations about the Products; (3) represented the Products had characteristics, ingredients, or benefits, they did not; (3) represented the Products were not deteriorated or altered, when they were; (4) represented the Products were particular standard or quality when they are not; and (5) advertised the Products with the intent not to sell them as advertised.

139. Defendant's acts and omissions violated Rhode Island's Deceptive Trade Practices Act, R.I. GEN. LAWS § 6- 13.1- 5.2(B), *et seq.* because Defendant: (1) caused likelihood of confusion or of misunderstanding as to the source, sponsorship, approval, or certification of the Products; (2) used deceptive representations in

connection with the Products; (3) represented the Products had sponsorship, approval, characteristics, ingredients, uses, benefits, they did not; (4) represented the Products were not deteriorated or altered, when they were; (5) represented the Products were of a particular standard, quality, or grade, when they were not; and (6) advertised the Products with the intent not to sell them as advertised.

140. Defendant's acts and omissions violated Washington's Consumer Protection Act, WASH. REV. CODE § 19.86.010, *et seq.*, which broadly prohibits Defendant from engaging in unfair methods of competition and unfair or deceptive acts or practices in the conduct of any trade or commerce.<sup>72</sup> Defendant's concealment of material health and safety information about the Products, which they knew or should have known, was injurious to the public interests of protecting public health and the public's right to know about any harmful constituents in the Products. Defendant's conduct caused harm to the Plaintiff, the Washington subclass members, and members of the public who bought the Products without knowing they degraded to benzene. Defendant's conduct has the capacity to cause harm to other people who buy the Products.

141. Had Defendant been truthful in their advertising, labeling, and packaging of the Products and not omitted material health and safety information about benzene in and formed from the Products, Plaintiff and the Subclass members would not have

---

<sup>72</sup> Under § 19.86.090, Washington consumers harmed by such practices may recover actual damages, the costs of the suit, including reasonable attorney's fees, and the court may, in its discretion, increase the award of damages to an amount up to three times the actual damages sustained.

bought the Products.

142. Defendant's acts and omissions and violations of these state consumer protection statutes are ongoing and continuing to cause harm.

143. Plaintiff, on behalf of himself, California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses suffered an ascertainable economic loss because of Defendant's misconduct because they bought the Products, they would not have bought but for Defendant's misrepresentations.

144. Because of Defendant's misconduct, Plaintiff, on behalf of herself, and the Subclass members, seeks recovery of their economic damages, attorneys' fees, punitive damages, and all other relief allowable under the law. The damages sought are ascertainable, uniform to the Subclass and can be measured and returned to the Subclass members.

**E. BREACH OF EXPRESS WARRANTY, on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses**

145. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

146. Plaintiff brings this cause of action on behalf of herself, and all members of the National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and

Washington Subclasses, all of whom are similarly situated consumers.

147. The Uniform Commercial Code § 2-313 provides that an affirmation of fact or promise made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain creates an express warranty that the goods shall conform to the promise. Defendant advertised and sold the Products as safe, pure, of good quality, and only containing the listed ingredients. Defendant's advertising, labels, containers, packaging, advertising, and online statements did not mention benzene, leading consumers to believe the Products were safe for their ordinary use. Defendant's affirmations were uniformly made to Plaintiff and the Class members by Defendant in the Products' advertising, labeling, packaging, and online statements and were part of the basis of the bargain between Defendant, the Plaintiff, the Class, and Subclass members.

148. Defendant's affirmations and promises are unlawful. When Defendant marketed, distributed, and sold the Products, Defendant knew, or should have known, the Products degraded to benzene under normal and expected use, handling, and storage conditions. Defendant knew, or should have known, the Products formed benzene and therefore did not conform to Defendant's express representations and warranties to consumers. Plaintiff, the Class, and Subclass members purchased the Products in reasonable reliance on Defendant's statements.

149. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and Subclass members, seek recovery of their economic damages, attorneys'

fees, punitive damages, restitution, and all other relief allowable by law, including an injunction to enjoin Defendant from continuing their fraudulent business practices.

The damages sought are ascertainable, uniform to the Class and Subclasses and can be measured and returned to the Class and Subclass members.

**F. BREACH OF IMPLIED WARRANTY, on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses**

150. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

151. Plaintiff brings this cause of action on behalf of herself, and all members of the National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

152. Defendant, as sellers of the Products, also made implied warranties including warranting the Products were of the same quality and purity represented on the labels, in advertising, and on Defendant's websites, were fit for the ordinary purpose of the Products and conformed to the promises made on the containers, labels, advertising, and websites that all ingredients were listed, and all warnings given.

153. Defendant advertised their Products as safe, when they knew, or should have known, the Products degraded to benzene. Defendant did not list benzene as an ingredient or contaminant anywhere on the Products or advertising. The Products are

not of the quality and purity represented by Defendant because the Products degrade to benzene under normal use, handling, and storage conditions.

154. Defendant did not tell Plaintiff or the Class or Subclass members the Products were not fit for their ordinary use because the Products, as advertised and sold by Defendant, degraded to benzene under normal and expected handling, use, and storage.

155. Defendant's affirmations that the Products were safe for use were uniformly made to the Plaintiff and the Class members in the Products' advertising, labeling, and packaging, and on Defendant's websites, which were part of the basis of the bargain.

156. Plaintiff, the Class, and Subclass members purchased the Products in reasonable reliance on Defendant's statements, affirmations, and omissions of material health and safety information.

157. Defendant's acts and omissions are ongoing and continuing to cause harm.

158. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and Subclass members, seek recovery of their actual damages, injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The damages sought are uniform to the Class and Subclasses and the actual damages can be measured and returned to consumers who bought Defendant's Products.

**G. UNJUST ENRICHMENT, on Behalf of the Nationwide Class and on Behalf of the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses**

159. Plaintiff realleges and incorporates all other paragraphs in this Complaint and further alleges:

160. Plaintiff brings this cause of action on behalf of herself, and all members of the National Class and the California, Connecticut, Hawaii, Illinois, Maryland, Massachusetts, Missouri, New York, Nevada, Pennsylvania, Ohio, Rhode Island, and Washington Subclasses, all of whom are similarly situated consumers.

161. Defendant has unjustly profited from their deceptive business practices and kept the profits from Plaintiff and the Class and Subclass members who purchased the Products.

162. Defendant requested and received a measurable economic benefit at the expense of Plaintiff, the Class, and Subclass members as payment for the Products. Defendant accepted the economic benefits from Plaintiff, the Class, and Subclass members knowing the economic benefit received was based on deception and omission of material human health and safety information.

163. There is no utility in Defendant's misconduct and Defendant's enrichment from the misconduct is unjust, inequitable, unconscionable, and against the strong public policy to protect consumers against fraud.



164. Because of Defendant's misconduct, Plaintiff, on behalf of herself, the Class and Subclass members, and the public seeks recovery of their actual damages, disgorgement of profits, injunctive relief, attorneys' fees, punitive damages, and all other relief allowable under the law. The damages sought are uniform to the Class and Subclasses and the actual damages can be measured and returned to consumers who bought Defendant's Products.

### **IX. PRAYER FOR RELIEF**

WHEREFORE, Plaintiff prays for judgment against Defendant:

1. That the Court determine this action may be maintained as a Class Action under Rule 23(a) and (b)(1), (2) and (3) of the Federal Rules of Civil Procedure;
2. That Defendant's misconduct be adjudged to have violated the state consumer protection laws identified herein;
3. That injunctive and declaratory relief be awarded against Defendant, including but not limited to an order prohibiting Defendant from engaging in the alleged misconduct;
4. That Defendant be ordered to disgorge profits and revenues derived from their course of misconduct and that such unjust enrichment be restored to the class and or distributed cy pres as the Court shall deem just and equitable;
5. That Plaintiff recover all compensatory damages and other damages sustained by Plaintiff;

6. That Plaintiff recover punitive damages as allowed by law;
7. That Plaintiff recover all statutory damages as allowed by law;
8. That Plaintiff recover their attorneys' fees and all costs of suit;
9. That Plaintiff recover all Statutory pre-judgment and post-judgment interest on any amounts; and
10. That all further relief as this Court may deem just and proper be granted.

DATED: Honolulu, Hawai'i, March 8, 2024.

*/s/ Robert M. Hatch*

\_\_\_\_\_  
MARGERY S. BRONSTER

ROBERT M. HATCH

R. BRENT WISNER, ESQ. (*Pro Hac Vice  
Forthcoming*)

STEPHANIE B. SHERMAN, ESQ. (*Pro Hac  
Vice Forthcoming*)

*Attorneys for Plaintiff and the Proposed  
Classes*